3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases.
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?
CRISPR Therapeutics (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Biotech Stocks to Buy Hand Over Fist in December
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500.
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 58.3% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%
Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum.
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies.
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft, I'm one of the biotech analysts at Jeffreys.
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.
